1. Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer
- Author
-
R N Harland, J M Morrison, Vivien H.C. Bramwell, Anthony Howell, and I Moneypenny
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Nausea ,Mitomycin ,medicine.medical_treatment ,Breast Neoplasms ,Vinblastine ,Gastroenterology ,Mitomycins ,Mitolactol ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Chemotherapy ,Antibiotics, Antineoplastic ,business.industry ,Mitomycin C ,Cancer ,Middle Aged ,medicine.disease ,Regimen ,Vomiting ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
A combination of dibromodulcitol 500 mg orally, mitomycin C 10 mg i.v. and vinblastine 10 mg i.v. all given on day 1 and repeated every 4 weeks was given to 40 patients with advanced breast cancer. All but one had received previous endocrine therapy. The response rate (CR + PR) in 24 previously untreated patients was 66% and was 37% in 16 previously treated patients. The survival of responders was significantly longer than non-responders. Thirty-two per cent of patients experienced nausea and vomiting. There was little myelosuppression or thrombocytopenia on the day of starting a new course of therapy but the haemoglobin dropped by 2 g/dl in 32% of patients during therapy. Thus DMV is a relatively non-toxic active regimen for patients with advanced breast cancer.
- Published
- 1984
- Full Text
- View/download PDF